American Health Packaging Initiates Class II Recall of Chlorpromazine HCl Tablets Over Packaging Contamination
American Health Packaging has initiated a Class II recall for specific lots of Chlorpromazine Hydrochloride Tablets, 200 mg, due to microbial contamination on packaging coil. This voluntary, firm-initiated action impacts nationwide U.S. distribution. Procurement and regulatory teams must assess supply chain stability for this critical antipsychotic, ensuring continuity while monitoring American Health Packaging's remediation efforts for compliance and product availability.
FDA Class II Recall: Chlorpromazine HCl Tablets Impacted by Packaging Contamination
Amerisource Health Services LLC has initiated a Class II recall, designated D-0650-2025, for specific lots of chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, distributed by American Health Packaging from its Columbus, Ohio facility. This voluntary, firm-initiated action commenced on August 27, 2025, and remains ongoing. The critical concern stems from the detection of a micro-organism on an auxiliary polyester coil utilized in the product's packaging process. It is important for procurement directors and regulatory affairs heads to note that, as per the firm's statement, no micro-organism was detected directly on the tablets themselves, mitigating immediate direct patient risk from the drug product's active pharmaceutical ingredient (API). This recall specifically targets 873 cartons of the 200 mg strength, packaged in 100 (10x10) blisterpacks per carton. The affected product carries NDC#: 60687-463-01 for the carton and 60687-463-11 for individual doses. Two distinct lots are implicated: Lot 1021640, with an expiration date of October 31, 2026, and Lot 1022639, expiring on January 31, 2027. Additional product NDCs associated with Chlorpromazine Hydrochloride from American Health Packaging include 60687-419, 60687-430, 60687-441, and 60687-452. For business development executives, this event underscores the critical importance of stringent quality control across the entire packaging supply chain, as even ancillary components can trigger significant regulatory actions and market disruption.
American Health Packaging's Role and Chlorpromazine HCl Market Significance
American Health Packaging, operating from Columbus, Ohio, serves as a key distributor of generic pharmaceutical products within the United States. This recall event specifically involves their Chlorpromazine Hydrochloride Tablets, USP, 200 mg, a medication approved under ANDA209755. Chlorpromazine Hydrochloride is a widely used antipsychotic drug, essential for managing various psychiatric conditions including schizophrenia, manic-depressive illness, and severe behavioral problems in children. Its role as a foundational medication means any supply disruption can have significant clinical implications for healthcare systems and patient populations reliant on its availability. For supply chain VPs, the involvement of a packaging component in this recall highlights the vulnerabilities inherent in the broader pharmaceutical supply chain, extending beyond API manufacturing to include excipients and packaging materials. While American Health Packaging is the distributor, the ultimate manufacturing site's packaging processes are under scrutiny. This incident prompts a review of supplier qualification processes for all components, not just active ingredients. Business development executives should recognize that maintaining an uninterrupted supply of such critical generic drugs is paramount for market stability and patient care, making robust quality systems a competitive differentiator.
Nationwide Distribution and Immediate Supply Chain Impact
The recalled lots of Chlorpromazine Hydrochloride Tablets were distributed nationwide across the USA. This extensive distribution pattern means that pharmacies, hospitals, and other healthcare providers throughout the country must promptly identify and quarantine affected stock. The FDA's Class II classification indicates that while the probability of serious adverse health consequences is remote, use of or exposure to the violative product may cause temporary or medically reversible adverse health consequences. Given that the micro-organism was found on the packaging coil and not the tablets, the immediate health risk is mitigated, but the potential for indirect contamination or patient concern remains. Procurement directors must initiate immediate internal audits to ascertain the presence of affected lots (1021640 and 1022639) within their inventory systems. This recall necessitates a rapid response to prevent further distribution and ensure patient safety. Regulatory affairs heads should guide their organizations on proper recall procedures, including communication with the recalling firm, Amerisource Health Services LLC, and adherence to FDA guidelines for product return or destruction. The nationwide scope amplifies the logistical challenges, requiring coordinated efforts across diverse healthcare networks to manage the affected 873 cartons effectively and minimize disruption to patient access for this essential medication.
Navigating Supply Disruption: Procurement Strategies for Essential Generics
In situations such as this Class II recall involving Chlorpromazine Hydrochloride, procurement directors must act decisively to mitigate potential supply chain vulnerabilities. While specific alternative suppliers for American Health Packaging's product are not detailed in the available intelligence, the strategic imperative is to ensure continuity of supply for this critical antipsychotic. Companies should immediately assess their current inventory levels of Chlorpromazine Hydrochloride, considering both the 200 mg strength and other available dosages, against projected demand. Developing a robust multi-source strategy is crucial. This involves identifying and qualifying alternative manufacturers or distributors of Chlorpromazine Hydrochloride, both domestically and internationally, to reduce reliance on a single source. Regulatory affairs teams play a vital role in expediting the qualification process for new suppliers, ensuring compliance with all necessary regulatory approvals and quality standards. Business development executives should explore opportunities for strategic partnerships or licensing agreements to secure alternative supply routes. The incident underscores that proactive supplier diversification and continuous monitoring of supplier quality metrics are indispensable for maintaining resilient pharmaceutical supply chains, especially for essential generic medications where market alternatives might be limited or require significant lead times for qualification.
Regulatory Context and Industry Compliance Landscape
While specific prior regulatory history for American Health Packaging is not available within our current knowledge graph, this Class II recall for Chlorpromazine Hydrochloride Tablets occurs within a broader landscape of heightened FDA scrutiny on pharmaceutical quality and manufacturing compliance. The detection of a micro-organism on packaging materials, even if not directly on the drug product, signals a lapse in environmental control or material quality assurance that the FDA takes seriously. This event parallels other recent regulatory actions, such as the Class II recall initiated by Essential Wellness Pharma for its Progesterone Injection due to sterility assurance failures, published in June 2026. Such incidents, though involving different products and companies, collectively emphasize the FDA's unwavering focus on preventing contamination and ensuring product integrity across the pharmaceutical industry. For regulatory affairs heads, this trend reinforces the need for comprehensive quality management systems, robust supplier qualification programs for all components, and proactive internal audits to identify and rectify potential compliance gaps before they escalate into recalls or more severe regulatory enforcement actions. The commercial implication for business development executives is that companies with demonstrably superior quality and compliance records will gain a significant competitive advantage in a market increasingly sensitive to regulatory risks.
Remediation Efforts and Future Supply Outlook for Chlorpromazine HCl
The recall of Chlorpromazine Hydrochloride Tablets by American Health Packaging is currently classified as 'Ongoing,' indicating that the firm is actively engaged in addressing the issue and implementing corrective actions. As a firm-initiated, voluntary recall, it suggests American Health Packaging took proactive steps upon discovering the foreign substance. The immediate next steps for the company involve a thorough investigation into the root cause of the micro-organism's presence on the auxiliary polyester coil, followed by the implementation of comprehensive Corrective and Preventive Actions (CAPA). This will likely include enhanced supplier audits for packaging materials, stricter incoming material quality checks, and potentially revised environmental monitoring protocols at the manufacturing site. For supply chain VPs and procurement directors, the 'Ongoing' status means continued monitoring of the situation is essential. While the direct product contamination risk is low, the recall could lead to temporary supply constraints if remediation efforts are protracted or if the issue affects other production lines. Business development executives should assess the potential for market shifts, as competitors may temporarily gain market share if American Health Packaging faces extended production or distribution halts. The FDA will closely monitor the firm's remediation progress to ensure the effectiveness of corrective actions and prevent recurrence, ultimately impacting the long-term availability and reliability of Chlorpromazine Hydrochloride from this supplier.